The potential of monoclonal antibodies for colorectal cancer therapy

Med Oncol. 2023 Aug 21;40(9):273. doi: 10.1007/s12032-023-02151-1.


Conventional chemotherapy has significant limitations for colorectal cancer (CRC) treatment, especially those who have developed metastatic recurrence CRC. A growing number of studies have investigated the potential use of monoclonal antibodies (mAbs) for CRC therapy. mAbs showing clinical benefits for CRC, making the treatment more selective with lower side effects without significant immunogenicity. In addition, recent advancements in antibody engineering strategies and the development of bifunctional or even trifunctional drugs have helped to overcome heterogeneity as the main challenge in cancer treatment. The current review discusses advances in applying mAbs for CRC therapy alone, combined, or with small molecules.

Keywords: Combination therapy; Monoclonal antibodies; Tumor heterogeneity.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Colonic Neoplasms*
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Rectal Neoplasms*


  • Antibodies, Monoclonal